HB1414, titled Cameron’s Law, would amend the Internal Revenue Code to increase the orphan drug tax credit from 25% to 50%. The bill is narrowly focused on Section 45C of the tax code, which provides a credit intended to encourage the development of drugs for rare diseases and conditions affecting small patient populations. The change would apply to taxable years beginning after enactment.
By doubling the credit rate, the bill would reduce federal tax liability for qualifying pharmaceutical companies and other eligible taxpayers that incur costs developing orphan drugs. The practical effect would be to make the orphan drug credit more valuable as an incentive for research and development in the rare-disease drug market, potentially encouraging additional investment in treatments that might otherwise be less financially attractive to develop.
Impact
The bill would amend Section 45C of the Internal Revenue Code of 1986 by changing the orphan drug tax credit rate from 25 percent to 50 percent, thereby altering federal tax law for qualifying drug development expenses. It would affect pharmaceutical manufacturers, biotech firms, and other taxpayers eligible for the credit, while indirectly impacting patients and advocacy groups focused on rare diseases through the incentive structure for drug development.
Sentiment
The available context suggests generally favorable treatment of the bill, as it was introduced with bipartisan support from four House members and referred to the House Committee on Ways and Means without recorded opposition or votes. The bill’s framing as “Cameron’s Law” and its focus on rare-disease treatment indicate a supportive policy goal centered on encouraging orphan drug development.
Contention
No committee transcript or vote record is available, so there is no documented debate in the provided materials. Potential points of contention, based on the policy itself, would likely concern the fiscal cost of expanding the tax credit, whether a larger subsidy is necessary to spur innovation, and whether the benefit would primarily accrue to drug კომპანიies rather than patients. Supporters would likely emphasize incentives for rare-disease research and expanded treatment options, while skeptics could question the efficiency and targeting of the tax expenditure.